These findings emphasized that DSP-0509 augmented anti-tumor immune responses by combining immunotherapy to suppress Tregs in the tumor microenvironment, while the effects of DSP-0509 alone primarily targeted Treg function and differentiation in the in vitro setting. This evidence concerns the gene DSP and neoplasm.